Compare Hewlett Packard Enterprise Co (HPE) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Mesoblast Limited — how do they compare? Hewlett Packard Enterprise Co trades at $73.46 (market cap $94.25B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Hewlett Packard Enterprise Co is far larger — about 53.9× Mesoblast Limited's market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Mesoblast Limited for 15 Days on average.
| HPE | MESO | |
|---|---|---|
Market Cap | $94.25B | $1.75B |
Volume | 16,060,854 | 239,027 |
Sector | Technology | Health |
52-Week High | $72.12 | $20.96 |
52-Week Low | $20.01 | $13.19 |
Typical Hold Time | 33 Days | 15 Days |
Enterprise Value | $108.28B | $1.83B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE's stock trades at $70.99, down 1.56% today but near its 52-week high, with a bullish technical outlook and strong AI-driven momentum. Recent earnings beats and a $1.2B AI server order from Vultr highlight robust demand. Valuation metrics show a P/E of 36.6 and P/S of 2.4, while cash flow trends indicate volatility with a net outflow of $9.25B in 2025 but a projected rebound in 2026.
The outlook is positive, driven by AI infrastructure growth and raised guidance, but risks include high debt levels and competitive pressures. Analyst consensus leans neutral with a $70.35 price target, suggesting cautious optimism amid near-term overbought conditions.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
